Investing.com - Arbutus Biopharma (NASDAQ:ABUS) reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Arbutus Biopharma announced earnings per share of $-0.120 on revenue of $5.95M. Analysts polled by Investing.com anticipated EPS of $-0.140 on revenue of $6.64M.
Arbutus Biopharma shares are down 16.73% from the beginning of the year, still down 62.15% from its 52 week high of $6.50 set on December 1, 2021.
Arbutus Biopharma shares lost 2.85% in pre-market trade following the report.
Arbutus Biopharma follows other major Healthcare sector earnings this month
Arbutus Biopharma's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar